

Lucas Ramon, Valentina Gligorijevic, Hadjer Loukil, Iain K Pemberton and Jane MacDougall
34 rue Carnot, 93160 Noisy-le-Grand, France

The KINDReD ASSOCIATION, an independent, charitable body, was set up in 2016 with the purpose of supporting promising preclinical candidates against Neglected Infectious Diseases (NIDs) to enter early phase clinical trials. The initial aim will be to promote a healthy portfolio of new clinical candidates, as the well-recognised high attrition rates in clinical trials means that many drugs may succumb to safety and efficacy issues. The Association will initially sponsor the molecules resulting from the European Community's Seventh Framework Programme under grant agreement No.602773 (Project KINDReD), which reaches term in August 2016. However, it is open to receive other advanced molecules from any source, and also against other neglected infectious diseases, on the understanding that there is absolute adherence to open source drug discovery with full freedom to operate accompanying any eventual intellectual property rights.

New partners are invited to join and contribute to building the strengths already established by the 14 international partners of the FP7 KINDReD consortium over the past three years. Together with new partners and new molecules we will combine our expertise and experience to provide accessible treatment for those who need it most.

NEGLECTED PARASITIC DISEASES



The trypanosomatid diseases; Leishmaniasis, Human African trypanosomiasis and Chagas disease, continue to impart a heavy toll on human health, affecting millions of people worldwide, particularly those living in the economically poorest countries. The handful of treatments available to control this enormous health burden is limited by serious adverse effects, high costs, difficulties in administration and the ever advancing spectre of drug resistance.



DRUG DEVELOPMENT

Most of the affected populations have very limited purchasing power (some living with approximately €1 per day), and thus attract little interest from the major pharmaceutical companies.

Currently, multiple treatments exist for these diseases, but none reach all the requirements of these diverse pathologies.

There is clearly an urgent need to develop safer and more effective chemotherapies to reduce the burden caused by neglected infectious diseases. Given the challenges and low success rate in moving drug discovery programmes to the patients, it is critical to have a broader portfolio of potential therapeutics moving forward in the pipeline, especially in the field of neglected diseases. The KINDReD Consortium via The KINDReD Association aims to fill this gap, combining academic excellence from topnotch research organisations and biotech expertise, to form an association of public-private partnerships aimed at delivering clinical candidates for these diseases.



DISEASE BURDEN

The neglected parasitic infections are a group of diseases that have been targeted by the European Commission, amongst others, as a priority for public health. These diseases are a major cause of morbidity and mortality in many developing countries and have serious consequences for the socio-economic development of these regions. Primary infections are not the only concern; secondary infections in HIV-infected and immuno-compromised patients also pose grave health risks. A major problem associated with these diseases is their prevalence in third world countries which are the least well-equipped to develop new drugs and invest in R&D.

AIMS OF THE ASSOCIATION

- Raise awareness of neglected infectious diseases
- Promote an exciting portfolio of new therapeutic candidates
- Provide funding to enable late stage preclinical candidates, from any source against any NID, to move towards registration and clinical approval
- Create a new climate of openness and sharing in the battle to combat neglected infectious diseases

JOIN-US

Everyone who shares the common objective of advancing promising laboratory-driven discoveries into clinical utility can support us.

All partners will be encouraged to use any capacity they have available to support the Association in order to strengthen its aims and the causes it defends.

FOLLOW-US

